NAD+ / NMN
Promising preclinical data with emerging human trial evidence.
Evidence Score
Score Breakdown
Want Molecular Data on Your NAD+ / NMN Response?
Join early access for mRNA-based monitoring — starting with GLP-1, live now.
Overview
Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are NAD+ precursors being investigated for anti-aging and metabolic health. While preclinical data is robust, human clinical trial evidence is still emerging. Several small RCTs have been published, but large-scale definitive trials are lacking.
Mechanism of Action
NMN is converted to NAD+ via the salvage pathway enzyme NMNAT. NAD+ serves as a cofactor for sirtuins (SIRT1-7), PARPs (DNA repair), and CD38. Sirtuin activation drives mitochondrial biogenesis (PGC-1α), oxidative stress resistance, and epigenetic regulation through histone deacetylation.
Evidence Base
Multiple small human RCTs (n=25–80) have demonstrated NAD+ level increases with NMN/NR supplementation. A 10-week RCT in postmenopausal women with prediabetes found improved muscle insulin sensitivity with NMN (Yoshino et al., Science 2021), while a 28-day trial of MIB-626, a pharmaceutical-grade NMN, found no change in insulin sensitivity. However, no large Phase III trials exist, and no NAD+ precursor is FDA-approved for any therapeutic indication. In September 2025, FDA reversed its 2022 position and confirmed that NMN may be marketed as a dietary supplement.
Gene Pathway Detail
NAD+ replenishment activates sirtuin-mediated gene regulation: SIRT1 deacetylates PGC-1α to promote mitochondrial biogenesis, SIRT3 regulates mitochondrial protein acetylation, and SIRT6 modulates DNA repair gene expression. Biomeme can monitor sirtuin pathway activation and mitochondrial gene expression to assess whether NAD+ supplementation is producing functional molecular changes.
mRNA Monitoring Insight
mRNA monitoring of sirtuin targets and mitochondrial biogenesis genes could provide molecular evidence of NAD+ pathway engagement, though blood-based signatures for NAD+ precursors are not yet established. This is particularly valuable for NAD+ precursors because blood NAD+ is not a routine clinical lab test, and gene expression changes may be the most accessible biomarker of functional response.
Safety Considerations
Generally well-tolerated in published studies. No serious adverse events reported in human trials to date. However, long-term safety data is limited. Theoretical concerns exist around PARP activation in cancer biology. Not FDA-approved for any indication.
FAQ
Does NMN actually work?
Quick Facts
- Category
- NAD+ Precursor (Non-Peptide)
- Score
- 71/100 (B)
- Gene Pathways
- 4 characterized
Monitor Your Peptide Response
Biomeme's transcriptomic platform tracks molecular pathway engagement. GLP-1 response testing is live now — NAD+ / NMN monitoring is coming soon.